What type of study is this?

This is a Animal Study study (also classified as: Experimental Study).

September 29, 2025Cancer Research

Abstract B039: Wild-Type IDH1 inhibition enhances PARP inhibitor sensitivity in pancreatic cancer

View Full Paper

Ask AI

Bookmark

Pharmacologic inhibition of wild-type isocitrate dehydrogenase 1 significantly enhances tumor sensitivity to PARP inhibitors.
The combination therapy led to a substantial suppression of tumor growth and improved survival in pancreatic cancer models.
Histone hypermethylation and impaired HR repair were noted following wild-type IDH1 blockade, mimicking a BRCA-mutated phenotype.
Analysis showed increased DNA damage and elevated apoptosis when combining IDH1 and PARP inhibitors in vitro.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This study demonstrates that blocking wild-type isocitrate dehydrogenase 1 sensitizes pancreatic cancer to PARP inhibitors, indicating potential for broader treatment strategies.

Cite This Study

Zarei et al. (2025) studied this question.

synapsesocial.com/papers/68da58dcc1728099cfd113af https://doi.org/10.1158/1538-7445.pancreatic25-b039

View Full Paper

Ask AI

Bookmark

Implication

This study demonstrates that blocking wild-type isocitrate dehydrogenase 1 sensitizes pancreatic cancer to PARP inhibitors, indicating potential for broader treatment strategies.

Abstract B039: Wild-Type IDH1 inhibition enhances PARP inhibitor sensitivity in pancreatic cancer

Key Points

Discussion

Implication

Cite This Study

Abstract B039: Wild-Type IDH1 inhibition enhances PARP inhibitor sensitivity in pancreatic cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider